Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis.
作者信息
Anderhalten Lina, Wohlrab Felix, Paul Friedemann
机构信息
Experimental and Clinical Research Center, A Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
出版信息
Lancet Reg Health Eur. 2024 Aug 22;44:101023. doi: 10.1016/j.lanepe.2024.101023. eCollection 2024 Sep.
Abstract
摘要
相似文献
1
Emerging MRI and biofluid biomarkers in the diagnosis and prognosis of multiple sclerosis.新兴的MRI和生物流体生物标志物在多发性硬化症诊断和预后中的应用
Lancet Reg Health Eur. 2024 Aug 22;44:101023. doi: 10.1016/j.lanepe.2024.101023. eCollection 2024 Sep.
2
Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review.创伤性脑损伤中的生物流体生物标志物：系统范围综述。
Neurocrit Care. 2021 Oct;35(2):559-572. doi: 10.1007/s12028-020-01173-1. Epub 2021 Jan 5.
3
Potential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids.多发性硬化症多种生物体液的潜在代谢生物标志物。
ACS Chem Neurosci. 2024 Mar 20;15(6):1110-1124. doi: 10.1021/acschemneuro.3c00678. Epub 2024 Feb 29.
4
Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response.多发性硬化症的精准医学：用于诊断、预后及治疗反应的生物标志物
Curr Opin Neurol. 2016 Jun;29(3):254-62. doi: 10.1097/WCO.0000000000000336.
5
Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis.多发性硬化症诊断、预后和疾病监测生物标志物的最新进展。
Neurol Clin. 2024 Feb;42(1):15-38. doi: 10.1016/j.ncl.2023.06.008. Epub 2023 Aug 5.
6
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.用于多发性硬化症临床复发的客观生物标志物：一种代谢组学方法。
Brain Commun. 2021 Oct 12;3(4):fcab240. doi: 10.1093/braincomms/fcab240. eCollection 2021.
7
Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.利用机器学习和基于MRI的生物标志物预测多发性硬化症的疾病进展和预后：综述
J Neurol. 2024 Oct;271(10):6543-6572. doi: 10.1007/s00415-024-12651-3. Epub 2024 Sep 12.
8
Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers.考虑阿尔茨海默病相关生物流体生物标志物的测量和解释中的性别差异。
J Appl Lab Med. 2020 Jan 1;5(1):158-169. doi: 10.1373/jalm.2019.030023.
9
Biofluid-based Biomarkers in Traumatic Brain Injury: A Narrative Review.创伤性脑损伤中基于生物流体的生物标志物：一篇叙述性综述。
Brain Neurorehabil. 2024 Mar 18;17(1):e8. doi: 10.12786/bn.2024.17.e8. eCollection 2024 Mar.
10
Lessons from immunotherapies in multiple sclerosis.多发性硬化症免疫疗法的启示。
Handb Clin Neurol. 2023;193:293-311. doi: 10.1016/B978-0-323-85555-6.00013-8.
引用本文的文献
1
Brain-derived blood biomarkers in multiple sclerosis-current trends and beyond.多发性硬化症中脑源性血液生物标志物——当前趋势及未来展望
Front Immunol. 2025 Jun 16;16:1569503. doi: 10.3389/fimmu.2025.1569503. eCollection 2025.
本文引用的文献
1
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis.炎症和神经退行性血清蛋白生物标志物可提高多发性硬化症临床和影像学疾病活动的检测灵敏度。
Nat Commun. 2024 May 20;15(1):4297. doi: 10.1038/s41467-024-48602-9.
2
Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.将视神经纳入多发性硬化症诊断标准：一项纵向、前瞻性、多中心研究。
Neurology. 2024 Jan 9;102(1):e200805. doi: 10.1212/WNL.0000000000207805. Epub 2023 Dec 13.
3
Cortical lesions at diagnosis predict long-term cognitive impairment in multiple sclerosis: A 20-year study.诊断时的皮质病变可预测多发性硬化症的长期认知障碍：一项20年的研究。
Eur J Neurol. 2023 May;30(5):1378-1388. doi: 10.1111/ene.15697. Epub 2023 Feb 19.
4
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.早期使用高效疾病修正疗法对多发性硬化症患者意义重大：专家观点。
J Neurol. 2022 Oct;269(10):5382-5394. doi: 10.1007/s00415-022-11193-w. Epub 2022 May 24.
5
Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.2017 年和 2010 年修订的 McDonald 标准在预测临床孤立综合征后 MS 诊断中的表现：MAGNIMS 研究。
Neurology. 2022 Jan 4;98(1):e1-e14. doi: 10.1212/WNL.0000000000013016. Epub 2021 Oct 29.
6
2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.2021 年 MAGNIMS-CMSC-NAIMS 关于多发性硬化症患者使用 MRI 的共识建议。
Lancet Neurol. 2021 Aug;20(8):653-670. doi: 10.1016/S1474-4422(21)00095-8. Epub 2021 Jun 14.
7
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.多发性硬化症的诊断：2017 年麦当劳标准修订版。
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
8
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.中央静脉征及其临床评估在多发性硬化诊断中的应用：北美多发性硬化影像学合作组的共识声明。
Nat Rev Neurol. 2016 Dec;12(12):714-722. doi: 10.1038/nrneurol.2016.166. Epub 2016 Nov 11.
Zotero 插件